ValuEngine cut shares of Corindus Vascular Robotics Inc (NYSEMKT:CVRS) from a hold rating to a sell rating in a research report released on Tuesday morning.

Other analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Corindus Vascular Robotics from a buy rating to a hold rating in a report on Monday, August 28th. BidaskClub downgraded shares of Corindus Vascular Robotics from a hold rating to a sell rating in a research report on Friday, September 8th. Finally, Cowen and Company set a $3.00 price objective on shares of Corindus Vascular Robotics and gave the company a buy rating in a research report on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating and three have given a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of $2.58.

Shares of Corindus Vascular Robotics (NYSEMKT:CVRS) opened at 1.59 on Tuesday. Corindus Vascular Robotics has a 12-month low of $0.40 and a 12-month high of $2.25. The firm’s market cap is $297.80 million. The stock’s 50 day moving average is $1.61 and its 200 day moving average is $1.49.

Corindus Vascular Robotics (NYSEMKT:CVRS) last posted its quarterly earnings data on Tuesday, August 8th. The medical equipment provider reported ($0.04) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The business had revenue of $2.26 million during the quarter, compared to analysts’ expectations of $3.10 million. Corindus Vascular Robotics had a negative net margin of 372.63% and a negative return on equity of 94.27%. Equities analysts expect that Corindus Vascular Robotics will post ($0.21) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Corindus Vascular Robotics Inc (CVRS) Downgraded by ValuEngine to “Sell”” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/corindus-vascular-robotics-inc-cvrs-downgraded-by-valuengine-to-sell/1607304.html.

A number of large investors have recently modified their holdings of CVRS. Goldman Sachs Group Inc. boosted its position in Corindus Vascular Robotics by 147.8% in the second quarter. Goldman Sachs Group Inc. now owns 58,824 shares of the medical equipment provider’s stock valued at $109,000 after buying an additional 35,086 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Corindus Vascular Robotics by 67.6% during the second quarter. Rhumbline Advisers now owns 80,868 shares of the medical equipment provider’s stock worth $150,000 after buying an additional 32,608 shares in the last quarter. New York State Common Retirement Fund increased its holdings in shares of Corindus Vascular Robotics by 334.6% during the second quarter. New York State Common Retirement Fund now owns 89,100 shares of the medical equipment provider’s stock worth $166,000 after buying an additional 68,599 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Corindus Vascular Robotics by 6.3% during the first quarter. Bank of New York Mellon Corp now owns 163,012 shares of the medical equipment provider’s stock worth $214,000 after buying an additional 9,684 shares in the last quarter. Finally, California State Teachers Retirement System increased its holdings in shares of Corindus Vascular Robotics by 34.4% during the second quarter. California State Teachers Retirement System now owns 148,558 shares of the medical equipment provider’s stock worth $276,000 after buying an additional 38,000 shares in the last quarter.

Corindus Vascular Robotics Company Profile

Corindus Vascular Robotics, Inc is engaged in robotic-assisted vascular interventions. The Company’s CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries.

Receive News & Ratings for Corindus Vascular Robotics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.